Aarti Pharmalabs Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 10 Aug 2026

Company page: Aarti Pharmalabs share price, financials & guidance record

Aarti Pharmalabs Limited reported a strong Q1 FY27 with significant Y-o-Y growth in revenue, EBITDA, and PAT, driven by record sales in Xanthine Derivatives and capacity expansions. The company completed debottlenecking projects and is bringing new Atali blocks online to support CDMO growth. While pricing pressures in API and potential declines in Xanthine realization per kg are noted, management expects overall sales growth and maintains a full-year EBITDA margin guidance of 22-25%.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 38.9%, net profit up 52.0% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	458	538	564	386	418 −9%	432 −20%	583 +3%	536 +39%
Expenses	364	409	418	293	344	330	470	400
EBITDA	94	129	146	93	74 −21%	102 −21%	113 −23%	136 +46%
Margin	20%	24%	26%	24%	18%	24%	19%	25%
Other income	4	5	-2	2	0	2	14	8
Interest	6	10	7	7	11	13	17	13
Depreciation	21	23	23	23	25	29	28	30
Profit before tax	72	101	115	65	39 −46%	63 −38%	82 −29%	101 +55%
Tax rate	24%	26%	23%	24%	28%	24%	25%	25%
Net profit	55	74	88	50	28 −49%	48 −35%	61 −31%	76 +52%
EPS	6.03	8.16	9.75	5.46	3.08	5.29	6.74	8.40

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls